ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
32 announcements with these filters
Krsnaa Diagnostics Ltd reported the successful passing of a special resolution via postal ballot approving the issuance of up to 16,21,000 convertible warrants to promoters.
Krsnaa Diagnostics executed a 15-year concession agreement with the Punjab Government to develop and operate PET-CT diagnostic facilities at four government hospitals.
Krsnaa Diagnostics received tax appellate orders for AY 2017-24 with aggregate disputed demands of ₹62.69 Crore. The company plans to file further appeals.
Krsnaa Diagnostics has filed its Business Responsibility and Sustainability Report for the financial year 2025-26 as required by regulatory listing obligations.
Krsnaa Diagnostics Limited has submitted the notice of its 16th Annual General Meeting, scheduled for September 28, 2026, along with the Annual Report for 2025-26.
Krsnaa Diagnostics issued a corrigendum to its Postal Ballot notice, providing additional disclosures regarding the proposed preferential issue of share warrants to promoters.
Krsnaa Diagnostics received an income tax rectification order for AY 2022-23, resulting in an additional demand of Rs. 12.10 Crore. The company intends to appeal.
Krsnaa Diagnostics will hold a postal ballot to seek shareholder approval for a preferential issue of convertible warrants totaling ₹91.75 Crore.
Krsnaa Diagnostics will seek shareholder approval via postal ballot to issue 16.21 lakh warrants to promoters at Rs. 566 per warrant, aggregating Rs. 91.75 Crore.
Krsnaa reported 22% revenue growth but suffered margin compression due to heavy front-ended costs for the Rajasthan project. Management pivots to 'long-term value' to deflect from current EBITDA and PAT dips.
Krsnaa Diagnostics reported 22% revenue growth in Q1 FY27, driven by expanding retail business and PPP project scaling, despite margin pressure from Rajasthan operationalization.
Krsnaa Diagnostics reported Q1 FY2027 revenue of ₹235.5 Crore, up 22% YoY. The Board also approved a preferential warrant issue for the Promoter Group.
Krsnaa Diagnostics Ltd reported revenue from operations of ₹235.5 Cr (+22.0% YoY) and net profit of ₹16.6 Cr (-19.0% YoY) for Q1 FY27.
Krsnaa Diagnostics Limited announced a board meeting scheduled for August 13, 2026, to discuss financial results for the quarter ending June 30, 2026, and fundraising proposals.
Krsnaa Diagnostics entered a PPP agreement with the Himachal Pradesh government to operate CT scan facilities at 34 health institutions, expanding from its previous 12 locations.
Krsnaa Diagnostics disclosed voting results for its postal ballot. Resolutions for re-appointing and appointing independent directors were passed with requisite majority.
ICRA has reaffirmed Krsnaa Diagnostics' credit ratings for bank facilities totaling ₹304.15 Crore. Long-term facilities are rated [ICRA]A(Stable) and short-term rated [ICRA]A1.
Krsnaa Diagnostics Limited issued a postal ballot notice for director re-appointments and commission approvals. Shareholders can vote electronically from June 5 to July 4, 2026.
Krsnaa Diagnostics reports 8% revenue growth and crossing ₹100cr PAT milestone in FY26, driven by PPP scaling and a sixfold growth in retail diagnostics.
Krsnaa Diagnostics reported FY26 revenue of ₹7,728 Mn (up 8% YoY) and PAT of ₹1,013 Mn (up 31% YoY). Strategy focuses on PPP model and aggressive retail expansion.
Krsnaa Diagnostics reported ₹772.8 Crore revenue for FY2026, with PAT growing 31% to ₹101.4 Crore. The company also declared a ₹2 final dividend per share.
Krsnaa Diagnostics filed its FY26 Annual Secretarial Compliance Report. The report confirms full adherence to SEBI regulations with no observed non-compliances or penalties.
Krsnaa Diagnostics recommended a final dividend of ₹2 per equity share for FY 2025-26. The record date and shareholder meeting for final approval are pending.
Krsnaa Diagnostics Ltd reported revenue from operations of ₹192.6 Cr (+3.5% YoY) and net profit of ₹41.7 Cr (+101.4% YoY) for Q4 FY26.
Krsnaa Diagnostics approved FY2026 financial results and recommended a final dividend of ₹2 per share. The company reported consolidated annual profit of ₹101.43 Crore.
Krsnaa Diagnostics received income tax demand notices totaling ₹11.31 Crore for two assessment years. The company is contesting these orders before appellate forums.
Krsnaa Diagnostics scheduled a board meeting for May 25, 2026. Directors will consider audited annual financial results and a potential final dividend declaration.
Krsnaa Diagnostics scheduled a board meeting for May 25, 2026. Directors will approve FY2026 audited financial results and recommend a potential dividend.
Krsnaa Diagnostics Ltd confirmed it does not fall under the 'Large Corporate' category as of March 31, 2026, per SEBI debt-raising norms. The company reported outstanding borrowings of ₹479.75 Crore and holds an 'A' credit rating from ICRA Limited.
Krsnaa Diagnostics Limited announced a leadership reorganization effective April 2026. This includes the re-appointment of Chetan Desai and new appointments of Raju Venkatraman, Jessie Paul, and CFO Chandra Prakash Singh. Simultaneously, Pallavi Bhatevara, Rajiva Ranjan Verma, and Chhaya Palrecha will cease their roles. The changes aim to strengthen governance and strategic expertise.